2016
DOI: 10.2147/ndt.s112542
|View full text |Cite
|
Sign up to set email alerts
|

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study

Abstract: PurposeThis single-arm, open-label study aimed to explore the effects of extended-release paliperidone on social and cognitive function in patients with schizophrenia.MethodsPaliperidone extended-release (flexible dose ranging from 3 to 12 mg/day orally) was administered for 24 weeks in patients with schizophrenia. Patient function was assessed using the personal and social performance scale, measurement and treatment research to improve cognition in schizophrenia initiative-consensus cognitive battery, positi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 30 publications
0
3
0
Order By: Relevance
“…Unfortunately, few studies specifically investigated the effect of paliperidone on cognitive domain. Available data showed that paliperidone, both ER and LAI, may improve this psychopathological domain in patients with schizophrenia (41)(42)(43)(44)(45)(46)(47). In contrast with this previous findings, our investigation failed to detect any effect of paliperidone on cognitive functions.…”
Section: Discussionmentioning
confidence: 99%
“…Unfortunately, few studies specifically investigated the effect of paliperidone on cognitive domain. Available data showed that paliperidone, both ER and LAI, may improve this psychopathological domain in patients with schizophrenia (41)(42)(43)(44)(45)(46)(47). In contrast with this previous findings, our investigation failed to detect any effect of paliperidone on cognitive functions.…”
Section: Discussionmentioning
confidence: 99%
“…Paliperidone is a relatively new atypical antipsychotic and is as effective as other atypical antipsychotics for schizophrenia with additional cognitive benefits. [17][18][19][20] Nonetheless, RCTs probing the efficacy of paliperidone for treatment-resistant schizophrenia are limited. The proven efficacy of olanzapine for this population and the similarity of the pharmacological profile of clozapine and olanzapine 21 made it intriguing to scrutinize the efficacy of paliperidone versus olanzapine.…”
mentioning
confidence: 99%
“…Paliperidone is a relatively new atypical antipsychotic and is as effective as other atypical antipsychotics for schizophrenia with additional cognitive benefits 17–20 . Nonetheless, RCTs probing the efficacy of paliperidone for treatment-resistant schizophrenia are limited.…”
mentioning
confidence: 99%